Working… Menu

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02086604
Recruitment Status : Active, not recruiting
First Posted : March 13, 2014
Last Update Posted : June 11, 2019
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 9, 2017
Estimated Study Completion Date : November 30, 2019